Antimalarials linked to retinal toxicity

Article

Hydroxychloroquine and chloroquine are strongly associated with retinal toxicity in patients with a lean body weight,

Hydroxychloroquine and chloroquine are strongly associated with retinal toxicity in patients with a lean body weight, according to a recent study published in the Archives of Ophthalmology.

The clinical findings suggested doctors should consider patient's body weight before administering either of the anti-malarial treatments. Dr Micheal Michaelides, et al, Oregon Retinal Degeneration Center, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA, studied 16 women aged between 44–85 for 7 years.

The research was carried out using fundus photography, visual field testing and electrophysiologic assessment on all patients. Six patients received spectral domain optical coherence tomography (OCT) and 4 patients received fundus autofluorescence imaging.

Results indicated that all patients had bilateral macular cone dysfunction. The most common symptom observed was difficulty reading and the fundus results varied from mild retinal pigment epithelial changes to bull's-eye maculopathy.

To lower the risk of retinal toxicity the findings advise the consideration of the patient's lean bodyweight when calculating the daily dosage of hydroxychloroquine sulphate and chloroquine phosphate.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.